Do cyclo-oxygenase 2 inhibitors increase the risk of cardiovascular events?: Commentary

Nature Clinical Practice Oncology

Volumn 2, Issue 9, 2005, Pages 434-435

  Chan, Andrew T ^a   Fuchs, Charles S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular events; Celecoxib; Colorectal adenoma; Colorectal cancer; COX2 inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

CANCER PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 27944474805     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0291     Document Type: Short Survey

References (5)

1. Hawk ET and Levin B (2005) Colorectal cancer prevention. J Clin Oncol 23: 378-391
2. Bresalier RS et al. (2005) A randomized trial of rofecoxib to prevent colorectal adenomas: The APPROVe trial. Gastroenterology 128: A35
3. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102
4. Spektor G and Fuster V (2005) Drug Insight: Cyclooxygenase 2 inhibitors and cardiovascular risk - where are we now? Nat Clin Pract Cardiovasc Med 2: 290-300
5. Chan AT et al. (2004) A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med 140: 157-166